Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Rituximab in Marginal Zone Lymphoma
2018-000187-28Phase 2Terminated
- Sponsor
- University Hospital Ulm
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and rituximab in marginal zone B-cell lymphoma (MZL), nodal marginal zone B-cell lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), sponsored by University Hospital Ulm. Primary endpoint: Complete response rate after end of treatment. Started Aug 2020; status: terminated.
02
Drugs
pembrolizumabrituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)nodal marginal zone B-cell lymphoma (NMZL)splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2018-000187-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000187-28.